Literature DB >> 11199321

Predictors of erythropoietin responsiveness in chronic hemodialysis patients.

M Tonelli1, P G Blake, N Muirhead.   

Abstract

The impact of dialysis intensity on erythropoietin (EPO) requirements is unclear. Previous work suggests that increased dialysis is associated with increased erythropoietin responsiveness (ERSP), but average dialysis intensity has increased since those publications. We hypothesized that ERSP would be independent of delivered Kt/V(urea) at current intensities of hemodialysis. We prospectively studied 135 stable chronic hemodialysis patients who receive iron and subcutaneous EPO dosed according to current guidelines. We collected biochemical, hematologic, and single pool urea kinetics data. ERSP was expressed as units per kilogram per week of EPO administered. Simple and multiple linear regression were used to identify characteristics predictive of ERSP. The mean age of the patients was 62 +/- 17 years (range, 17-90 years); 68 of 135 (50.3%) were women, and 120 of 135 (88.9%) were Caucasian. Mean delivered Kt/V(urea) was 1.60 +/- 0.49, with 102 of 135 (75.6%) of patients with a delivered Kt/V(urea) > 1.3. Univariate linear regression showed seven significant independent predictors of erythropoietin requirements. Low serum albumin (p < 0.001), low serum calcium (p = 0.002), high serum phosphate (p = 0.004), and high serum iPTH (p = 0.007) were all associated with lower levels of ERSP. Lower ERSP was also correlated with lower hemoglobin and lower serum iron and transferrin saturation. Delivered dialysis (Kt/ V(urea)) was not a significant predictor of ERSP (p = 0.61). Multivariate regression confirmed low serum albumin (p < 0.01), high serum phosphate (p = 0.001), high immunoreactive parathyroid hormone (p = 0.025), and low transferrin saturation (p < 0.0005) as predictors of low ERSP, and also found high serum ferritin to be correlated with low ERSP (p = 0.016). We found no relationship between erythropoietin responsiveness and intensity of hemodialysis in this population of patients with a mean delivered Kt/V(urea) of 1.6. This may indicate a threshold effect beyond which more dialysis will not improve ERSP. However, markers of an underlying inflammatory state and of secondary hyperparathyroidism were associated with decreased response to erythropoietin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11199321     DOI: 10.1097/00002480-200101000-00017

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  11 in total

1.  Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients.

Authors:  Michio Kuwahara; Youhei Arai; Eriko Takehara; Yasunori Sasaki; Tomoharu Yoshimine; Keita Kusaka; Satomi Shikuma; Wataru Akita; Shinichi Uchida
Journal:  Clin Exp Nephrol       Date:  2015-10-28       Impact factor: 2.801

2.  Secondary hyperparathyroidism and anemia in children treated by hemodialysis.

Authors:  Lorie B Smith; Jeffrey J Fadrowski; Chanelle J Howe; Barbara A Fivush; Alicia M Neu; Susan L Furth
Journal:  Am J Kidney Dis       Date:  2010-02       Impact factor: 8.860

3.  Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.

Authors:  Tadao Akizawa; Keiko Tanaka-Amino; Tetsuro Otsuka; Yusuke Yamaguchi
Journal:  Am J Nephrol       Date:  2021-10-08       Impact factor: 3.754

4.  Evaluation of beta globin mRNA as an early marker of haemoglobin response to epoetin treatment.

Authors:  Gunnar Birgegård; Fredrik Dahl; Bengt Glimelius; Ulf Landegren
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

5.  The role of short daily hemodialysis in the control of hyperphosphatemia, secondary hyperparathyroidism and anemia.

Authors:  Jie-Long Jiang; Wei Ren; Yan Li; Guang-Yi Liu; Cai-Ping Zhou; Ke-Liang Su; Wei Chen; Ke Wang; Li-Jun Ni; Zhao Hu
Journal:  Int Urol Nephrol       Date:  2013-04-17       Impact factor: 2.370

6.  Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.

Authors:  Ryan D Kilpatrick; Cathy W Critchlow; Steven Fishbane; Anatole Besarab; Catherine Stehman-Breen; Mahesh Krishnan; Brian D Bradbury
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 8.237

Review 7.  Safety issues with intravenous iron products in the management of anemia in chronic kidney disease.

Authors:  Amir Hayat
Journal:  Clin Med Res       Date:  2008-12

8.  Erythropoietin stimulating agents in the management of anemia of chronic kidney disease.

Authors:  Amir Hayat; Dhiren Haria; Moro O Salifu
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

9.  Maintaining over time clinical performance targets on anaemia correction in unselected population on chronic dialysis at 20 Italian centres. Data from a retrospective study for a clinical audit.

Authors:  Silvia Soffritti; Giorgia Russo; Stefano Cantelli; Giuseppe Gilli; Luigi Catizone
Journal:  BMC Nephrol       Date:  2009-10-24       Impact factor: 2.388

10.  Managing anemia in lymphoma and multiple myeloma.

Authors:  Gunnar Birgegård
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.